<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120624</url>
  </required_header>
  <id_info>
    <org_study_id>MC1562</org_study_id>
    <secondary_id>NCI-2017-00615</secondary_id>
    <secondary_id>MC1562</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03120624</nct_id>
  </id_info>
  <brief_title>VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer</brief_title>
  <official_title>Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human&#xD;
      interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib&#xD;
      phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that&#xD;
      has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted&#xD;
      ability to spread to tumor cells and not to healthy cells. It also contains a gene for a&#xD;
      protein, NIS, which helps the body concentrate iodine making it possible to track where the&#xD;
      virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells.&#xD;
      Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in&#xD;
      treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the optimal dose schedule, safety and tolerability as measured by the&#xD;
      incidence of significant toxicity of VSV-hIFNbeta-NIS in immunocompetent patients with&#xD;
      metastatic and/or recurrent endometrial cancer (EC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicity profile of VSV-hIFNbeta-NIS (alone and in combination with&#xD;
      ruxolitinib phosphate [ruxolitinib]).&#xD;
&#xD;
      II. To determine the time course of viral gene expression and virus elimination, and the&#xD;
      biodistribution of virally infected cells at various times points after infection with&#xD;
      VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib) using Tc-99m pertechnetate&#xD;
      planar and single photon emission computed tomography (SPECT)/computed tomography (CT) or&#xD;
      fluorine F18 tetrafluoroborate (TFB)-positron emission tomography (PET) imaging.&#xD;
&#xD;
      III. To assess virus replication, viremia; viral shedding in urine and respiratory&#xD;
      secretions; and virus persistence after intravenous (IV) administration of VSV-hIFNbeta-NIS&#xD;
      (alone and in combination with ruxolitinib).&#xD;
&#xD;
      IV. To monitor humoral responses to the injected virus. V. To estimate the tumor response&#xD;
      rate and overall survival.&#xD;
&#xD;
      CORRELATIVE OBJECTIVES:&#xD;
&#xD;
      I. To determine the pharmacokinetic (PK) profile of VSV-IFNbeta-NIS in patients with EC by&#xD;
      measurement of VSV-IFNbeta-NIS in blood by reverse transcriptase polymerase chain reaction&#xD;
      (RT-PCR).&#xD;
&#xD;
      II. To characterize the pharmacodynamics (PD) of VSV-IFNbeta-NIS by way of measuring serum&#xD;
      interferon-beta and also VSV-RT-PCR of VSV-IFNbeta-NIS listed above.&#xD;
&#xD;
      III. Assess CD8+ T cell (both general and VSV-IFNbeta-NIS specific) and natural killer (NK)&#xD;
      cell responses.&#xD;
&#xD;
      IV. Gene expression analysis pre- and post-virotherapy. V. Evaluate transcription of&#xD;
      interferon mediated genes (protein kinase R, the death receptor-TRAIL, 2'-5'&#xD;
      oligoadenylate/RNAse L proteins, heat shock proteins [Hsp 60/70/90], major histocompatibility&#xD;
      class antigens and IRF-7).&#xD;
&#xD;
      VI. Assess presence of VSV in tumor and normal tissues subsequent to administration of IV&#xD;
      VSV-IFNbeta-NIS.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of VSV-hIFNbeta-NIS. Patients are randomized to 1 of&#xD;
      2 arms.&#xD;
&#xD;
      ARM A: Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days,&#xD;
      patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later,&#xD;
      undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18&#xD;
      tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive,&#xD;
      patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and&#xD;
      SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging&#xD;
      between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of&#xD;
      accessible NIS image-positive tumors may occur after any imaging. Patients also undergo&#xD;
      image-guided biopsy of accessible tumor on day 29.&#xD;
&#xD;
      ARM B: Patients receive ruxolitinib phosphate orally (PO) twice daily (BID) on days -3 to 9.&#xD;
      Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients&#xD;
      receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole&#xD;
      body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and&#xD;
      undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium&#xD;
      Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine&#xD;
      F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days&#xD;
      if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may&#xD;
      occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day&#xD;
      29.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at day 29, every 3 months until&#xD;
      disease progression and then every 6 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib phosphate)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4. Defined as the highest safely-tolerated dose level where at most one patient out of six experiences dose limiting toxicities (DLT) with the next higher dose level having at least 2 of 6 patients who have experienced DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Graded according to the NCI CTCAE version 4. Frequency distributions and other descriptive measures will form the basis of the analysis of these variables. Simple summary statistics will be supplemented with Kaplan-Meier survival estimates and related confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of clinical responses</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as complete response, partial response, or stable disease assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Will be summarized by simple descriptive summary statistics across all patients in each group as well as by dose level and primary type of cancer (EC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral replication and shedding in blood, throat washings, urine, and buccal swabs assessed via quantitative reverse transcriptase polymerase chain reaction</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Descriptive statistics and scatterplots will form the basis of presentation of these variables. Correlations with other outcome measures will be carried out by standard parametric and non-parametric tests (e.g. Pearson's and Spearman's rho).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution and kinetics of virus spread and NIS gene expression in vivo</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Assessed via single-photon emission computed tomography/computed tomography. Will be correlated with tumor distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until treatment related grade 3+ toxicity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Graded according to the NCI CTCAE version 4. Simple summary statistics will be supplemented with Kaplan-Meier survival estimates and related confidence intervals. The effect of dose and ancillary dichotomized covariates such as age will be explored using logrank testing involving one covariate at a time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hematologic nadirs (white blood cells, absolute neutrophil count, platelets)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Simple summary statistics will be supplemented with Kaplan-Meier survival estimates and related confidence intervals. The effect of dose and ancillary dichotomized covariates such as age will be explored using logrank testing involving one covariate at a time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Metastatic Endometrial Carcinoma</condition>
  <condition>Recurrent Endometrial Adenocarcinoma</condition>
  <condition>Recurrent Endometrial Carcinoma</condition>
  <condition>Recurrent Endometrial Clear Cell Adenocarcinoma</condition>
  <condition>Recurrent Endometrial Endometrioid Adenocarcinoma</condition>
  <condition>Recurrent Endometrial Mixed Cell Adenocarcinoma</condition>
  <condition>Recurrent Endometrial Serous Adenocarcinoma</condition>
  <condition>Recurrent Endometrial Undifferentiated Carcinoma</condition>
  <condition>Recurrent Uterine Corpus Carcinosarcoma</condition>
  <condition>Stage IV Uterine Corpus Cancer AJCC v7</condition>
  <condition>Stage IVA Uterine Corpus Cancer AJCC v7</condition>
  <condition>Stage IVB Uterine Corpus Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Undergo image-guided biopsy</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>Biopsy Type</other_name>
    <other_name>BIOPSY_TYPE</other_name>
    <other_name>Bx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorine F 18 Tetrafluoroborate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>18F-Tetrafluoroborate</other_name>
    <other_name>18F-TFB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Planar Imaging</intervention_name>
    <description>Undergo whole body planar imaging</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo TFB-PET</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>Oncolytic VSV-hIFNbeta-NIS</other_name>
    <other_name>Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter</other_name>
    <other_name>Voyager-V1</other_name>
    <other_name>VSV-expressing hIFNb and NIS</other_name>
    <other_name>VSV-hIFNb-NIS</other_name>
    <other_name>VSV-hIFNbeta-NIS</other_name>
    <other_name>VV1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>INCB-18424</other_name>
    <other_name>INCB18424</other_name>
    <other_name>Jakafi</other_name>
    <other_name>Oral JAK Inhibitor INCB18424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Phosphate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>INCB-18424 Phosphate</other_name>
    <other_name>Jakafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium Tc-99m Sodium Pertechnetate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)</arm_group_label>
    <arm_group_label>Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)</arm_group_label>
    <other_name>Pertscan-99m</other_name>
    <other_name>Sodium Pertechnetate (Na99mtco4)</other_name>
    <other_name>Tc 99m Generator</other_name>
    <other_name>Ultra-Technekow FM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Measurable stage IVA, stage IVB (with or without measurable disease) or recurrent&#xD;
             (with or without measurable disease) endometrial carcinoma&#xD;
&#xD;
               -  NOTE: histologic confirmation of the original primary tumor is required; patients&#xD;
                  with the following histologic epithelial cell types are eligible: Endometrioid&#xD;
                  adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell&#xD;
                  adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not&#xD;
                  otherwise specified (NOS)&#xD;
&#xD;
               -  NOTE: measurable disease is defined by Response Evaluation Criteria in Solid&#xD;
                  Tumors (RECIST) (version 1.1)&#xD;
&#xD;
          -  Group A only: Largest tumor diameter =&lt; 5 cm&#xD;
&#xD;
               -  NOTE: Group B patients have no maximum tumor size&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/uL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Platelet count (PLT) &gt;= 100,000/uL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 mg/dL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2 x upper limit&#xD;
             of normal (ULN) (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
               -  NOTE: if baseline liver disease, Child Pugh score not exceeding class A&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  International normalized ratio (INR)/prothrombin time (PT), activated partial&#xD;
             thromboplastin time (aPTT) =&lt; 1.4 x ULN (obtained =&lt; 14 days prior to registration)&#xD;
             unless on therapeutic warfarin then INR/PT =&lt; 3.5&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2&#xD;
&#xD;
          -  Willingness to provide mandatory biological specimens for research purposes&#xD;
&#xD;
          -  Prior therapy:&#xD;
&#xD;
               -  Any number of prior chemotherapy regimens and/or targeted therapies and/or prior&#xD;
                  external beam radiation therapy and/or prior hormonal therapy for endometrial&#xD;
                  cancer are allowed provided the last treatment was &gt; 4 weeks prior to&#xD;
                  registration&#xD;
&#xD;
               -  Vaginal brachytherapy may have been administered at any time prior to&#xD;
                  registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Availability of and patient acceptance of curative therapy&#xD;
&#xD;
          -  Active infection, including any active viral infection, =&lt; 5 days prior to&#xD;
             registration&#xD;
&#xD;
          -  Active or latent tuberculosis or hepatitis&#xD;
&#xD;
          -  Known untreated or symptomatic brain metastases&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  Chemotherapy &lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Targeted biologic therapy &lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Immunotherapy &lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Any viral or gene therapy prior to registration&#xD;
&#xD;
               -  External beam radiotherapy &lt; 4 weeks prior to registration&#xD;
&#xD;
                    -  NOTE: Vaginal brachytherapy may be performed at any time prior to&#xD;
                       registration&#xD;
&#xD;
          -  New York Heart Association classification III or IV, known symptomatic coronary artery&#xD;
             disease, or symptoms of coronary artery disease on systems review, or uncontrolled&#xD;
             current cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia&#xD;
             [SVT])&#xD;
&#xD;
          -  Active central nervous system (CNS) disorder or seizure disorder or known CNS disease&#xD;
             or neurologic symptomatology&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or&#xD;
             immunosuppression&#xD;
&#xD;
          -  History of hepatitis B or C or chronic hepatitis&#xD;
&#xD;
          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy&#xD;
             considered investigational (used for a non-Food and Drug Administration [FDA] approved&#xD;
             indication and in the context of a research investigation)&#xD;
&#xD;
          -  Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled&#xD;
             steroids&#xD;
&#xD;
          -  Exposure to household contacts =&lt; 15 months old or household contact with known&#xD;
             immunodeficiency&#xD;
&#xD;
          -  Any of the following because this study involves an investigational agent whose&#xD;
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are&#xD;
             unknown:&#xD;
&#xD;
               -  Pregnant persons or persons of reproductive ability who are unwilling to use&#xD;
                  effective contraception&#xD;
&#xD;
               -  Nursing persons&#xD;
&#xD;
          -  Any other pathology or condition that the principal investigator deems to negatively&#xD;
             impact treatment safety&#xD;
&#xD;
          -  Any immunotherapy-related adverse events Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) &gt; grade 1 at the time of registration&#xD;
&#xD;
          -  Receipt of a live virus vaccine =&lt; 2 months prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie N Bakkum-Gamez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie N. Bakkum-Gamez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
    <mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

